Medical

A study published in the journal Nicotine and Tobacco Research found that 32% of smokers using a nicotine MDI plus a nicotine patch quit for 6 months compared to 18% of smokers using a placebo MDI and a nicotine patch. The study enrolled 502 adults who smoked at least 9 cigarettes per day. According to the authors, "The present trial demonstrates that a simple … [Read more...] about Study shows nicotine inhaler helps smokers quit

US biotechnology company NeOnc Technologies has announced the initiation of a Phase 1/2a clinical trial of NEO100 intranasal perillyl alcohol (POH) for the treatment of glioblastoma multiforme (GBM), an aggressive brain cancer. Five-year survival for patients with GBM is only 3-5%. The trial is expected to enroll approximately 40 patients in total, and the first … [Read more...] about NeOnc Technologies initiates Phase 1/2a clinical trial of intranasal perillyl alcohol for glioblastoma

An EMA Pharmacovigilance Risk Assessment Committee (PRAC) review of published data from controlled clinical trials, observational studies, and meta-analyses has concluded that all inhaled corticosteroid (ICS) products appear to carry a similar risk of pneumonia when used to treat COPD patients but that the benefits of ICS treatment for COPD outweigh the risks. … [Read more...] about EMA review finds that all ICS products carry similar risk of pneumonia but that benefits outweigh the risks

Sunovion has announced that the GOLDEN-3 and GOLDEN-4 Phase 3 clinical trials of SUN-101 glycopyrrolate inhalation solution for the treatment of moderate-to-very severe COPD both met their primary endpoints. SUN-101, delivered via the PARI eFlow handheld nebulizer, demonstrated statistically significant improvement in FEV1 versus placebo after 12 weeks for both the 50 … [Read more...] about Phase 3 trials of Sunovion’s nebulized glycopyrrolate meet primary endpoints

Mast Therapeutics has announced that the Duke Clinical Research Institute will serve as the coordinating center for the Heart Failure Clinical Research Network (HFN) as it conducts a Phase 2 study of AIR001 sodium nitrite inhalation solution. Earlier this year, Mast reported positive results from a Phase 2a AIR001 for the treatment of heart failure that was conducted … [Read more...] about Mast Therapeutics announces Phase 2 study of AIR001by the Heart Failure Clinical Research Network

An analysis of data from Boehringer Ingelheim's WISDOM study showed that withdrawal of ICS for COPD patients using the Spiriva Handihaler tiotropium bromide DPI plus salmeterol is associated with a higher exacerbation rate in patients with ≥ 4% eosinophils in their blood, according to a new article published in Lancet Respiratory Medicine. Approximately 20% of the … [Read more...] about Eosinophil levels predict effect of ICS added to Spiriva + LABA on exacerbations

In a leading article published in the Archives of Disease in Childhood, Andrew Bush and Louise Fleming of Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College London assert that "the diagnosis of asthma has been trivialized and inhalers dispensed for no good reason, and have become almost a fashion accessory," which has contributed to … [Read more...] about Respiratory specialists call out overdiagnosis of childhood asthma and overprescription of inhalers